Star Imaging and Path Lab Ltd
Incorporated in 2004, Star Imaging and Path Lab Limited is a healthcare company providing diagnostic services across a wide range of medical tests.[1]
- Market Cap ₹ 122 Cr.
- Current Price ₹ 70.0
- High / Low ₹ 152 / 46.0
- Stock P/E 6.32
- Book Value ₹ 66.6
- Dividend Yield 0.00 %
- ROCE 26.0 %
- ROE 23.6 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Stock is trading at 1.05 times its book value
- Company has a good return on equity (ROE) track record: 3 Years ROE 32.1%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has high debtors of 206 days.
- Working capital days have increased from 95.3 days to 142 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Part of BSE SME IPO
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 69 | 58 | 79 | 84 | 89 | |
| 54 | 52 | 55 | 54 | 55 | |
| Operating Profit | 15 | 6 | 23 | 29 | 33 |
| OPM % | 21% | 10% | 30% | 35% | 37% |
| 0 | 0 | 1 | 0 | 1 | |
| Interest | 2 | 2 | 3 | 3 | 2 |
| Depreciation | 4 | 3 | 5 | 5 | 6 |
| Profit before tax | 9 | 1 | 16 | 21 | 26 |
| Tax % | 33% | 35% | 23% | 26% | 27% |
| 6 | 1 | 12 | 16 | 19 | |
| EPS in Rs | 41.93 | 3.87 | 82.80 | 11.80 | 11.07 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 15% |
| TTM: | 6% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 222% |
| TTM: | 21% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 29% |
| 3 Years: | 32% |
| Last Year: | 24% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 14 | 17 |
| Reserves | 17 | 17 | 30 | 34 | 99 |
| 30 | 27 | 31 | 33 | 21 | |
| 10 | 16 | 20 | 18 | 17 | |
| Total Liabilities | 58 | 61 | 82 | 98 | 154 |
| 15 | 19 | 22 | 21 | 25 | |
| CWIP | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| 43 | 42 | 60 | 77 | 128 | |
| Total Assets | 58 | 61 | 82 | 98 | 154 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| 14 | 5 | 18 | -6 | 23 | |
| -4 | -7 | -7 | -4 | -13 | |
| -7 | -5 | 2 | -0 | 36 | |
| Net Cash Flow | 3 | -7 | 13 | -10 | 46 |
| Free Cash Flow | 10 | -2 | 11 | -10 | 13 |
| CFO/OP | 119% | 95% | 95% | -2% | 91% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|
| Debtor Days | 85 | 110 | 152 | 222 | 206 |
| Inventory Days | 24 | ||||
| Days Payable | 398 | ||||
| Cash Conversion Cycle | 85 | 110 | 152 | 222 | -167 |
| Working Capital Days | 6 | -13 | 23 | 121 | 142 |
| ROCE % | 6% | 34% | 35% | 26% |
Insights
In beta| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| CT Scan Machines Infrastructure Number ・Standalone data |
|
||
| MRI Machines Infrastructure Number ・Standalone data |
|||
| Number of PPP Centers Number ・Standalone data |
|||
| Pathology Tests Number of Tests |
|||
| Radiology Tests - CT Scan Number of Tests |
|||
| Radiology Tests - MRI Number of Tests |
|||
| Radiology Tests - X-Ray Number of Tests |
|||
| Total Diagnostic Centers Number ・Standalone data |
|||
Extracted by Screener AI
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
2d - Intimation of Availability of Text Transcript On Analysts / Institutional Investors / Organisations meet- Earnings Call.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
25 May - 25 May 2026 earnings call audio recording for audited FY2026 results available on company website.
-
Announcement under Regulation 30 (LODR)-Investor Presentation
25 May - Investor Presentation for Half and Financial Year ended 31st March 2026
- Outcome Of The Board Meeting Held Today I.E. Friday, 22 May 2026 22 May
-
Board Meeting Outcome for Outcome Of The Board Meeting Held Today I.E. Friday, 22 May 2026
22 May - Board approved audited FY26 standalone and consolidated results; auditors issued unmodified opinion, with Rs 1,512.80 lakh IPO proceeds unutilized.
Concalls
-
May 2026Transcript PPT
Business Profile[1]
Star Imaging and Path Lab Limited (originally Janta X-Ray Clinic) is a Delhi-based diagnostic healthcare service provider offering pathology, radiology, cardiology, and neurology services. The company operates through B2C, B2B, and B2G models, with NABL-accredited facilities.